A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

• ClinicalTrials.gov Identifier: NCT02519348
• Recruitment Status: Active, not recruiting
• First Posted: August 10, 2015
• Results First Posted: December 6, 2021
• Last Update Posted: January 17, 2023
• Sponsor: MedImmune LLC
• Information provided by (Responsible Party): MedImmune LLC

Study Description

Brief Summary:

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.

Condition or disease	Intervention/treatment	Phase
Hepatocellular Carcinoma	Biological: Tremelimumab; Biological: Durvalumab; Biological: Bevacizumab	Phase 2

Detailed Description:

The study will comprise of 6 parts. Participants in Part 1A (safety run-in cohort), Part 1B (efficacy-gating cohort), Part 2A, and Part 4 will receive weight-based dosing regimens; and participants in Part 2B and Part 3 will receive fixed dosing regimens. Part 1A Stage 2 of the study may start after the first 3 participants in Stage 1 have been observed on study for at least 4 weeks. In addition, a separate cohort of participants will be enrolled in mainland China (China cohort) once global recruitment in Part 2A will be closed.

• In Part 1 (both 1A and 1B), participants will receive tremelimumab 1 mg/kg intravenous (IV) every 4 weeks (Q4W) 4 doses and durvalumab 20 mg/kg Q4W.

• In Part 2A, participants will be randomized in a 1:1:1 ratio to receive:

  • Durvalumab 20 mg/kg Q4W
  • Tremelimumab 10 mg/kg Q4W × 7 doses followed by every 12 weeks (Q12W)
  • Tremelimumab 1 mg/kg Q4W × 4 doses + durvalumab 20 mg/kg Q4W, followed by durvalumab 20 mg/kg Q4W
• In China cohort, Part 2A study design will be followed.
• In Part 2B, participants will receive tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W.

• In Part 3, participants will be randomized in a 2:2:1:2 ratio to receive:

  • Durvalumab 1500 mg Q4W
  • Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W
  • Tremelimumab 750 mg Q4W for 7 doses followed by Q12W
  • Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W, followed by durvalumab 1500 mg Q4W.

Following protocol amendment 5, enrollment into 'Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg' arm will close. Participants will be randomized at a ratio of 2:1:2 in 'Durvalumab 1500 mg Q4W', 'Tremelimumab 750 mg Q4W for 7 doses followed by Q12W', and 'Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W' arms, respectively.

• In Part 4, participants will receive durvalumab 1120 mg (15 mg/kg) + bevacizumab 15 mg/kg every 3 weeks (Q3W).

Participants will receive the treatment until confirm progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.

All participants will be followed for survival until the end of study visit (last participant discontinues the study treatment).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 433 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma
• Actual Study Start Date: October 19, 2015
• Actual Primary Completion Date: November 6, 2020
• Estimated Study Completion Date: December 29, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg; Participants in Part 1A (safety run-in cohort) and Part 1 B (efficacy-gating cohort) will receive tremelimumab 1 mg/kg every 4 weeks (Q4W) 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Tremelimumab; Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736
Experimental: Parts 2 and 3: Durvalumab 1500 mg; Participants will receive durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736
Experimental: Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg; Participants will receive tremelimumab 300 mg 1 dose and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Tremelimumab; Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736
Experimental: Parts 2 and 3: Tremelimumab 750 mg; Participants will receive tremelimumab 750 mg Q4W 7 doses followed by every 12 weeks (Q12W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Tremelimumab; Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Experimental: Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg; Participants will receive tremelimumab 75 mg Q4W 4 doses and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first. Participant recruitment to this arm was closed following protocol amendment 5.	Biological: Tremelimumab; Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736
Experimental: Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg; Participants will receive durvalumab 1120 mg and bevacizumab 15 mg/kg every 3 weeks (Q3W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first	Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736; Biological: Bevacizumab; Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
Experimental: China Cohort: Durvalumab 20 mg/kg; Participants will receive durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736
Experimental: China Cohort: Tremelimumab 10 mg/kg; Participants will receive tremelimumab 10 mg/kg Q4W 7 doses followed by Q12W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Tremelimumab; Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
Experimental: China Cohort: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg; Participants will receive tremelimumab 1 mg/kg Q4W 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.	Biological: Tremelimumab; Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Biological: Durvalumab; Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.; Other Name: MEDI4736

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: From Day 1 to Day 28 after first dose of study drug ]
   A DLT was defined as treatment-related toxicity that occurred during DLT evaluation period including: any Grade 4 immune-related adverse event (irAE), any Grade 3 colitis or any Grade 3 noninfectious pneumonitis irrespective of duration, any >= Grade 2 pneumonitis that does not resolve to <= Grade 1 within 7 days of initiation of maximal supportive care, any other Grade 3 irAE (excluding colitis or pneumonitis) that does not downgrade to Grade 2 within 7 days after onset of the event despite optimal medical management including systemic corticosteroids or does not downgrade to <= Grade 1 or baseline within 14 days, liver transaminase elevation > 8 × upper limit of normal (ULN) or total bilirubin > 5 × ULN, aspartate aminotransferase or alanine aminotransferase > 3 × ULN with concurrent increase in total bilirubin > 2 × ULN without evidence of cholestasis or alternative explanations, and any >= Grade 3 non-irAE (except for the protocol stated conditions).
2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. There will be no updated results for this outcome measure at the time of end of study.
3. Number of Participants With Clinically Important Changes in Hematology and Clinical Chemistry Parameters [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Participants with clinically important Common Terminology Criteria for Adverse Events (CTCAE) grade changes to 3 or 4 in hematology and chemistry parameters are reported. There will be no updated results for this outcome measure at the time of end of study.
4. Number of Participants With Abnormal Vital Signs Reported as TEAEs [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Vital sign assessment included pulse rate, blood pressure, temperature, weight, and respiratory rate. Vital signs abnormalities recorded as TEAEs are reported. There will be no updated results for this outcome measure at the time of end of study.
5. Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Number of participants with ECG abnormalities recorded as TEAEs are reported. There will be no updated results for this outcome measure at the time of end of study.

Secondary Outcome Measures :

1. Overall Objective Response Rate (ORR) Based on Investigator Assessments and Blinded Independent Central Review (BICR) [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Disease assessments based on investigator assessments and BICR review were determined by using Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) guidelines. The ORR is defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR). The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as >= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression in-between. There will be no updated results for this outcome measure at the time of end of study.
2. Disease Control Rate (DCR) Based on Investigator Assessments and BICR [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Disease assessments based on investigator assessments and BICR review were determined by using RECIST v1.1 guidelines. The DCR is defined as a BOR of confirmed CR, confirmed PR, or stable disease (SD). A confirmed CR is defined as two CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as two PRs (>= 30% decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. There will be no updated results for this outcome measure at the time of end of study.
3. Time to Response (TTR) Based on Investigator Assessments and BICR [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Disease assessments based on investigator assessments and BICR review were determined by using RECIST v1.1 guidelines. The TTR is defined as the time from randomization for Parts 2A and 3, and time from first dose for Parts 1, 2B, and 4 until the first documentation of a subsequently confirmed OR (confirmed CR or confirmed PR). A confirmed CR is defined as two CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as two PRs (>= 30% decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The TTR was estimated using Kaplan-Meier method. There will be no updated results for this outcome measure at the time of end of study.
4. Duration of Response (DoR) Based on Investigator Assessments and BICR [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   The DoR is defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) based on investigator assessments and BICR review by using RECIST v1.1 or death in absence of disease progression. A confirmed CR is defined in above outcome measures. The PD is defined at least 20% increase in sum of diameters of target lesions (compared with nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. For participants who were alive and no documented PD at the time of data cutoff for analysis, DoR was censored at the last evaluable disease assessment date. The DoR was estimated using Kaplan-Meier method. There will be no updated results for this outcome measure at the time of end of study.
5. Time to Progression (TTP) Based on Investigator Assessments and BICR [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Disease assessments based on investigator assessments and BICR review were determined by using RECIST v1.1 guidelines. The TTP was defined as the time from randomization for Parts 2A and 3, and time from first dose for Parts 1, 2B, and 4 to the first documentation of radiographic disease progression. However, if the participant died without tumor progression, they were censored at the time of death. Participants with no documented PD by the data cutoff date for TTP analysis were censored at the date of their last evaluable disease assessment. The TTP was estimated using Kaplan-Meier method. There will be no updated results for this outcome measure at the time of end of study.
6. Progression Free Survival (PFS) Based on Investigator Assessments and BICR [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   Disease assessments based on investigator assessments and BICR review were determined by using RECIST v1.1 guidelines. The PFS is defined as the time from randomization for Parts 2A and 3, and time from first dose for Parts 1, 2B, and 4 until the first documentation of radiographic disease progression or death due to any cause, whichever occurs first. The PD is defined at least 20% increase in the sum of diameters of target lesions (compared with the nadir at 2 consecutive visits with an absolute increase of 5 mm), unequivocal progression of existing non-target lesions or new lesion. Participants who were alive with no documented PD by the data cutoff date for PFS analysis were censored at the date of their last evaluable disease assessment. The PFS was estimated using Kaplan-Meier method. There will be no updated results for this outcome measure at the time of end of study.
7. Overall Survival (OS) [ Time Frame: From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) ]
   The OS is defined as the time from randomization for Parts 2A and 3, and time from first dose for Parts 1, 2B, and 4 until death due to any cause. If there was no death reported for a participant by the data cut-off date for overall survival analysis, OS was censored at the last known alive date. The OS was estimated using Kaplan-Meier method. There will be no updated results for this outcome measure at the time of end of study.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female participants
2. 18 years and older (Japan-20 years and older)
3. Confirmed hepatocellular carcinoma (HCC) based on histopathological findings from tumor tissues. Advanced HCC with diagnosis confirmed pathologically or with noninvasive methods.
4. Immunotherapy-naïve
5. Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI. For arm 5 only: Have not received any prior systemic therapy for HCC.

Exclusion Criteria:

1. Prior exposure to immune-mediated therapy
2. Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy
3. Gastrointestinal bleeding (eg, esophageal varices or ulcer bleeding) within 12 months
4. Ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose.
5. Main portal vein thrombosis (Vp4) as documented on imaging
6. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment
7. Active or prior documented autoimmune or inflammatory disease with some exceptions
8. Current or prior use of immunosuppressive medication within 14 days with some exceptions

Contacts and Locations

Locations

United States, Arizona

Research Site

Phoenix, Arizona, United States, 85054

United States, California

Research Site

San Francisco, California, United States, 94158

United States, Connecticut

Research Site

New Haven, Connecticut, United States, 06510

United States, Florida

Research Site

Jacksonville, Florida, United States, 32224

Research Site

Tampa, Florida, United States, 33612

United States, Indiana

Research Site

Indianapolis, Indiana, United States, 46202

United States, Massachusetts

Research Site

Boston, Massachusetts, United States, 02114

United States, New York

Research Site

New York, New York, United States, 10065

Research Site

Stony Brook, New York, United States, 11794

United States, North Carolina

Research Site

Durham, North Carolina, United States, 27705

United States, Oregon

Research Site

Portland, Oregon, United States, 97213

United States, Pennsylvania

Research Site

Philadelphia, Pennsylvania, United States, 19107

Research Site

Philadelphia, Pennsylvania, United States, 19111

United States, Tennessee

Research Site

Nashville, Tennessee, United States, 37203

United States, Texas

Research Site

Dallas, Texas, United States, 75390

United States, Washington

Research Site

Seattle, Washington, United States, 98109

China

Research Site

Hangzhou, China, 310016

Research Site

Nanjing, China, 210002

Research Site

Shanghai, China, 200032

Hong Kong

Research Site

Hong Kong, Hong Kong

Research Site

Sha Tin, Hong Kong

Italy

Research Site

Benevento, Italy, 82100

Research Site

Milano, Italy, 20133

Research Site

Roma, Italy, 00168

Japan

Research Site

Chuo-ku, Japan, 104-0045

Research Site

Kashiwa, Japan, 277-8577

Research Site

Osakasayama-shi, Japan, 589-8511

Korea, Republic of

Research Site

Busan, Korea, Republic of, 49241

Research Site

Jung-gu, Korea, Republic of, 41944

Research Site

Seongnam-si, Korea, Republic of, 13620

Research Site

Seoul, Korea, Republic of, 03080

Research Site

Seoul, Korea, Republic of, 05505

Research Site

Seoul, Korea, Republic of, 06273

Research Site

Seoul, Korea, Republic of, 06351

Singapore

Research Site

Bukit Merah, Singapore, 169610

Research Site

Singapore, Singapore, 119074

Research Site

Singapore, Singapore, 308433

Spain

Research Site

Barcelona, Spain, 08035

Research Site

Barcelona, Spain, 08036

Research Site

Cordoba, Spain, 14004

Research Site

Pamplona, Spain, 31008

Taiwan

Research Site

Kaohsiung City, Taiwan, 83301

Research Site

Taipei, Taiwan, 100

Research Site

Taoyuan City, Taiwan, 333

Sponsors and Collaborators

MedImmune LLC

Investigators

• Study Director: MedImmune, LLC MedImmune, LLC; MedImmune LLC

  Study Documents (Full-Text)

Documents provided by MedImmune LLC:

Study Protocol  [PDF] January 4, 2019

Statistical Analysis Plan  [PDF] November 27, 2020

More Information

Additional Information:

Related Info 

Related Info 

Related Info 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22.

• Responsible Party: MedImmune LLC
• ClinicalTrials.gov Identifier: NCT02519348
• Other Study ID Numbers: D4190C00022
• First Posted: August 10, 2015
• Results First Posted: December 6, 2021
• Last Update Posted: January 17, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP)
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
• Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
• URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MedImmune LLC:

Hepatocellular Carcinoma; Immunotherapy; Antibodies, Monoclonal; Tremelimumab; MEDI4736; Durvalumab

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Hepatocellular; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Bevacizumab; Durvalumab; Tremelimumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors